Veterinary pharmacy seeks formal specialty recognition

Veterinary pharmacy’s long-running bid for formal specialty status has entered a consequential new phase. What began as a discussion point in Clinician’s Brief is now an active petition before the Board of Pharmacy Specialties, which is considering whether veterinary pharmacy should become a board-certified pharmacy specialty. The petition was submitted in January 2026 by the American College of Veterinary Pharmacists, the International College of Veterinary Pharmacists, and the Society of Veterinary Hospital Pharmacists, and BPS opened public comment in late February. (pharmacytimes.com)

The move matters because veterinary pharmacy sits in an unusual space: it supports veterinary medicine, but the credentialing question is being decided through pharmacy’s specialty framework, not AVMA’s veterinary specialty system. AVMA recognizes veterinary specialty organizations for veterinarians, and its most recent published count lists 22 AVMA-recognized specialty organizations and 46 specialties. Veterinary pharmacy is not among them, which helps explain why advocates are pursuing recognition through BPS instead. (avma.org)

This latest effort follows groundwork laid in 2024, when BPS announced a veterinary pharmacy job analysis panel to determine whether there was enough interest and practice distinction to justify a new specialty. BPS said then that if the findings supported the case, it would issue a profession-wide call for a petition. That sequence is exactly what happened: a job analysis was completed, BPS advanced the issue for formal petition review, and the process is now in the public comment stage. Under BPS’s own roadmap, the next steps after comment are board review, a decision, and, if approved, creation of a specialty council to develop eligibility standards and an exam. (prnewswire.com)

Supporters are making a detailed argument that veterinary pharmacy is distinct enough to merit formal recognition. In the petition summary and related statements, they describe veterinary pharmacists as professionals who manage direct patient care for nonhuman patients while also addressing food-chain residue concerns, zoonotic disease, species-specific toxicology, and major interspecies differences in pharmacokinetics and pharmacodynamics. They also argue that the practice setting is broader than many veterinarians may assume, spanning community and compounding pharmacies, veterinary clinics, teaching hospitals, zoos, aquariums, industry, NASA, NIH, CDC, and regulatory agencies. ACVP has framed the effort as a patient-safety and public-health issue, not just a professional branding exercise. (pharmacytimes.com)

That public-health framing lines up with a broader point Clinician’s Brief recently highlighted in its discussion of global access to veterinary care: veterinary services are not just about individual pets, but also about zoonotic disease surveillance, food security, and animal welfare. In that context, pharmacy expertise is part of the infrastructure that supports safe, effective treatment when animals do reach care. Advocates for specialty recognition are effectively arguing that medication-use systems in veterinary medicine have become important enough—and specialized enough—to warrant their own formal standard.

Industry reaction, at least from the pharmacy side, has been openly supportive. In comments reported by Pharmacy Times, petitioner Gigi Davidson said BPS needs specific examples showing how the specialty improves care, public health, and workforce demand, rather than generic endorsements. ACVP has also urged pharmacists to tie comments to the petition’s formal criteria, including need, demand, and specialized knowledge. That emphasis suggests advocates know the case will likely rise or fall on practical evidence that this is a distinct, scalable discipline, not simply a niche interest area. (pharmacytimes.com)

Why it matters: For veterinary professionals, this is less about titles and more about medication safety, workflow, and access. AVMA’s prescribing guidance explicitly encourages open communication with pharmacists and notes the regulatory complexity around veterinary prescriptions, including state pharmacy and veterinary board rules and federal extralabel drug use requirements. In day-to-day practice, many clinics still run into friction around species-appropriate dosing, excipient safety, compounding standards, and even basic prescription processing. If BPS recognition moves forward, it could create a more visible pool of pharmacists with validated advanced training in those issues, which may improve collaboration with DVMs and reduce medication errors for animal patients. (avma.org)

The timing also matters because veterinary therapeutics are getting more sophisticated. Clinician’s Brief recently noted the rapid rise of monoclonal antibodies in veterinary medicine, from lokivetmab’s early impact in atopic dermatitis to newer use in pain management and other emerging indications. These targeted biologics are very different from traditional small-molecule prescribing and add another layer of handling, counseling, and protocol complexity. At the same time, antimicrobial stewardship remains a live issue, with growing interest in “wait-and-see” prescribing models that aim to reduce unnecessary antibiotic use while preserving good outcomes. Both trends point in the same direction: veterinary medication management is becoming more nuanced, not less.

There are also strategic implications for a profession facing rising therapeutic complexity and broader workforce pressures. As veterinary medicine uses more compounded preparations, biologics, and species-specific protocols, the gap between general pharmacy knowledge and veterinary pharmacotherapy becomes harder to ignore. Advocates say only about 75 pharmacists currently hold the more limited ICVP credential described in reporting, which underscores how small the formally credentialed pipeline remains today. A broader BPS pathway could expand training incentives and standardization, though that would still take time even if the petition is approved. And like the rest of veterinary medicine, that pipeline exists within a larger conversation about training costs and career economics; Clinician’s Brief has also recently pointed to concern over veterinary student debt and debt-to-income realities, a reminder that workforce development is shaped not just by interest, but by affordability and long-term career planning. (pharmacytimes.com)

What to watch: Public comments close on April 1, 2026, at 5:00 p.m. ET, and ACVP says BPS expects to render a decision within six months. If BPS approves the petition, the field would move from recognition to implementation, with a specialty council tasked with building the certification program, eligibility criteria, and exam blueprint. For veterinarians, the practical question is whether that eventually translates into better pharmacy support in clinics, referral hospitals, and community dispensing settings—especially as treatment options expand and the profession continues to balance access, stewardship, and workforce constraints. (vetmeds.org)